T-Cell Lymphomas  Pipeline Review, H1 2013

T-Cell Lymphomas Pipeline Review, H1 2013

Apr 2013 Global Markets Direct Lymphoma222 Pages Price :
$ 2000

Global Markets Directs, \'T-Cell Lymphomas Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas. 

T-Cell Lymphomas Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for T-Cell Lymphomas.
  • A review of the T-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the T-Cell Lymphomas pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
T-Cell Lymphomas Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for T-Cell Lymphomas 12
T-Cell Lymphomas Therapeutics under Development by Companies 14
T-Cell Lymphomas Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
T-Cell Lymphomas Therapeutics Products under Development by Companies 22
T-Cell Lymphomas Therapeutics Products under Investigation by Universities/Institutes 25
Companies Involved in T-Cell Lymphomas Therapeutics Development 26
Kyowa Hakko Kirin Co., Ltd. 26
Seattle Genetics, Inc. 27
Emergent BioSolutions Inc. 28
Infinity Pharmaceuticals, Inc. 29
ZIOPHARM Oncology, Inc. 30
Millennium Pharmaceuticals, Inc. 31
Eisai Co., Ltd. 32
Nippon Kayaku Co., Ltd. 33
Pfizer Inc. 34
Teva Pharmaceutical Industries Limited 35
Celgene Corporation 36
Onyx Pharmaceuticals, Inc. 37
TopoTarget A/S 38
Mundipharma International Limited 39
Pharmacyclics, Inc. 40
Sareum Holdings plc 41
Innate Pharma SA 42
Spectrum Pharmaceuticals, Inc. 43
Chipscreen Biosciences Ltd 44
Nerviano Medical Sciences S.r.l. 45
Xencor, Inc. 46
PharmaMar, S.A. 47
T-Cell Lymphomas Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 55
CEP-28122 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
navitoclax - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
alisertib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
brentuximab vedotin - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
brentuximab vedotin - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
brentuximab vedotin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
crizotinib - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
HBI-8000 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
HBI-8000 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
carfilzomib - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
belinostat - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
mogamulizumab - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
PCI-34051 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
forodesine hydrochloride - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
darinaparsin - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
denileukin diftitox - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
pralatrexate - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
IPH-41 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
XmAb-2513 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
zanolimumab - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
plitidepsin - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
belinostat + [bortezomib] - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
A-dmDT390-bisFv - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
lenalidomide - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
romidepsin - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
romidepsin - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
alefacept - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
IPI-145 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
CEP-37440 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
brentuximab vedotin + [cyclophosphamide] + [doxorubicin] + [prednisone] + [vicristine sulfate] - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 123
Aurora Kinases + ALK Kinase Program - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
brentuximab vedotin + [cyclophosphamide] + [doxorubicin] + [prednisone] - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 126
Peripheral Blood Stem Cell Transplantation - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
IMTOX-25 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
mogamulizumab + mLSG15 - Drug Profile 129
Product Description 129
Mechanism of Action 130
R&D Progress 130
NMS-E628 - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
SOM-0350 - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
Belinostat + [Rituximab] + [ibritumomab tiuxetan] - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
SOM-0666 - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
AKR-302 - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
SOM-0558 - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
NK-314 - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
T-Cell Lymphomas Therapeutics Drug Profile Updates 139
T-Cell Lymphomas Therapeutics Discontinued Products 207
T-Cell Lymphomas Therapeutics - Dormant Products 208
T-Cell Lymphomas Product Development Milestones 210
Featured News & Press Releases 210
Nov 15, 2012: Celgene\'s Istodax Receives CHMP Negative Opinion For Treatment Of Peripheral T-cell Lymphoma 210
Nov 05, 2012: Millennium To Present Data On Adcetris At American Society Of Hematology Annual Meeting 211
Nov 05, 2012: Seattle Genetics To Present Data On Adcetris And Antibody-Drug Conjugates At American Society Of Hematology Annual Meeting 211
Nov 05, 2012: Seattle Genetics To Present Data On Adcetris And Antibody-Drug Conjugates At American Society Of Hematology Annual Meeting 213
Oct 31, 2012: Takeda And Millennium Announce European Conditional Marketing Authorization For Adcetris 215
Oct 15, 2012: Topotarget Obtains EU Orphan Drug Designation For Belinostat To Treat Peripheral T-cell Lymphoma 216
Oct 01, 2012: Millennium And Seattle Genetics Highlight Data From ADCETRIS Trial In Patients With Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma 216
Sep 24, 2012: Spectrum Pharma Provides Update On Belinostat Registrational Trial For Treatment Of Relapsed/Refractory Peripheral T-Cell Lymphoma 218
Sep 21, 2012: Topotarget Announces Belinostat Meets Primary Endpoint In Pivotal Lymphoma Trial 219
Jul 20, 2012: Millennium And Takeda Announce Positive CHMP Opinion For Conditional Approval Of ADCETRIS In Europe 219

Appendix 221

Methodology 221
Coverage 221
Secondary Research 221
Primary Research 221
Expert Panel Validation 221
Contact Us 222
Disclaimer 222

List of Table


Number of Products Under Development for T-Cell Lymphomas, H1 2013 12
Products under Development for T-Cell Lymphomas Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2013 17
Comparative Analysis by Late Stage Development, H1 2013 18
Comparative Analysis by Mid Clinical Stage Development, H1 2013 19
Comparative Analysis by Early Clinical Stage Development, H1 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Development by Companies, H1 2013 (Contd..1) 23
Products under Development by Companies, H1 2013 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2013 25
Kyowa Hakko Kirin Co., Ltd., H1 2013 26
Seattle Genetics, Inc., H1 2013 27
Emergent BioSolutions Inc., H1 2013 28
Infinity Pharmaceuticals, Inc., H1 2013 29
ZIOPHARM Oncology, Inc., H1 2013 30
Millennium Pharmaceuticals, Inc., H1 2013 31
Eisai Co., Ltd., H1 2013 32
Nippon Kayaku Co., Ltd., H1 2013 33
Pfizer Inc., H1 2013 34
Teva Pharmaceutical Industries Limited, H1 2013 35
Celgene Corporation, H1 2013 36
Onyx Pharmaceuticals, Inc., H1 2013 37
TopoTarget A/S, H1 2013 38
Mundipharma International Limited, H1 2013 39
Pharmacyclics, Inc., H1 2013 40
Sareum Holdings plc, H1 2013 41
Innate Pharma SA, H1 2013 42
Spectrum Pharmaceuticals, Inc., H1 2013 43
Chipscreen Biosciences Ltd, H1 2013 44
Nerviano Medical Sciences S.r.l., H1 2013 45
Xencor, Inc., H1 2013 46
PharmaMar, S.A., H1 2013 47
Assessment by Monotherapy Products, H1 2013 48
Assessment by Combination Products, H1 2013 49
Assessment by Stage and Route of Administration, H1 2013 51
Assessment by Stage and Molecule Type, H1 2013 54
T-Cell Lymphomas Therapeutics Drug Profile Updates 139
T-Cell Lymphomas Therapeutics Discontinued Products 207
T-Cell Lymphomas Therapeutics Dormant Products 208
T-Cell Lymphomas Therapeutics Dormant Products (Contd..1) 209

List of Chart


Number of Products under Development for T-Cell Lymphomas, H1 2013 12
Products under Development for T-Cell Lymphomas Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 17
Late Stage Products, H1 2013 18
Mid Clinical Stage Products, H1 2013 19
Early Clinical Stage Products, H1 2013 20
Discovery and Pre-Clinical Stage Products, H1 2013 21
Assessment by Monotherapy Products, H1 2013 48
Assessment by Combination Products, H1 2013 49
Assessment by Route of Administration, H1 2013 50
Assessment by Stage and Route of Administration, H1 2013 51
Assessment by Molecule Type, H1 2013 52
Assessment by Stage and Molecule Type, H1 2013 53

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top